AI in Pathology Is a $164M Market Heading for $1.4B: Why Oncology Is About 80% of the Tools

18 hours ago

2 min read

Pathology is where most cancer diagnoses are confirmed, and it is under growing pressure from rising biopsy volumes and a limited supply of pathologists. AI is moving in to help. One published projection values the global AI in pathology market at about USD 163.6 million in 2026, rising to roughly USD 1.37 billion by 2036 at a 23.7% CAGR, an expansion of about 8.4 times.

Oncology Is the Core Use Case

Oncology accounts for about 80% of AI pathology tools in development or on the market, with cardiovascular and infectious disease applications also listed. The logic is straightforward: cancer drives the biopsy workload, and deep-learning models, particularly convolutional neural networks, are well suited to analysing whole slide images.

Software Leads, Services Grow Fastest

By component, software is expected to hold the largest share in 2026, while services are projected to grow fastest as laboratories need help with integration, validation and workflow change. North America is expected to hold the largest regional share in 2026, with Asia-Pacific growing fastest through 2036.

Adoption Is Still Early

The same source estimates that digital pathology adoption stood at only about 20 to 25% in the US and Europe as of 2025, and notes that the FDA had authorized 1,451 AI-enabled medical devices as of March 2026, most of them in radiology, with pathology described as an emerging area. Barriers include high costs for scanners, IT infrastructure and software licenses, resistance to changing established diagnostic workflows, and the data-management challenge of very large slide image files.

Players and Opportunities

Vendors profiled include Leica Biosystems, Roche, Indica Labs, Proscia, PathAI and Paige AI. Opportunities highlighted include AI for drug discovery and companion diagnostics, and a shift toward multimodal AI that combines pathology images with real-world evidence.

What It Means for Your Strategy

For vendors, the near-term opening is oncology workflows inside labs that are already digitizing, with services revenue from implementation. For investors and health systems, the question is how fast digitization spreads, because AI tools depend on it. As with any early-stage market, estimates are small and sensitive to definitions: the source gives no 2025 base value, so treat the headline figures as indicative.